Trinity Biotech's Trinovium unit partners with Echelon on AI data center cooling
The collaboration, announced August 17, 2026, will pair Trinovium's fluid technology with Echelon's hyperscale data center infrastructure to develop liquid cooling systems for AI computing.
Trinity Biotech plc (NASDAQ: TRIB) announced on August 17, 2026 that its subsidiary Trinovium, described as a subsidiary focused on advanced liquid cooling solutions and fluid intelligence systems for next-generation AI data centers1, has entered a strategic collaboration agreement with Echelon Data Centres, which the release calls a leading hyperscale data center owner, developer and operator1, to jointly build liquid cooling systems aimed at AI and high-density computing use cases.
The two companies plan to combine Trinovium's fluid manufacturing and analytical know-how with Echelon's infrastructure experience, and will work together on developing and refining liquid cooling technologies meant to tackle the thermal management issues tied to AI workloads and next-generation computing architectures1.
Echelon's scale is substantial: the company says it is developing one of the largest hyperscale data center portfolios in Europe, with more than 700 MW currently in development, over 1.4 GW of secured capacity, and more than 4 million square meters of data center space across multiple development regions.1
According to the release, the parties expect to commence development activities imminently, with initial focus areas including direct-to-chip cooling fluids, thermal management systems and modular liquid cooling solutions optimized for AI and high-performance computing deployments.1
Trinity Biotech noted that Trinovium has developed an initial direct-to-chip liquid cooling formulation designed around three core performance requirements and the relevant Open Compute Project guidelines: ultra-high-purity, highly stable aqueous chemistry; corrosion inhibition and coolant system protection; and healthcare-level consistency and traceability.1 The company also said it is building a fluid health and system intelligence platform drawing on Trinity Biotech's broad analytical technology portfolio, including connected electrochemical sensing and mass spectrometry capabilities acquired through recent strategic transactions.1
The forward-looking statements in the filing note that success depends on Trinity Biotech's ability to successfully develop and commercialize data center cooling & thermal management solutions for AI and high-performance computing including its ability to realize the expected technical and commercial benefits of the collaboration with Echelon Data Centres1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.